AbbVie (ABBV) and Xilio Therapeutics (XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Its forward dividend yield is a juicy 3.4%. For a while, though, AbbVie might not have been viewed as a fabulous pick by many investors. Humira, the company's top-selling drug for years ...

AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian tariffs and has increased its dividend for 30 consecutive years.

AbbVie's cash-cow immunology product Humira has its first biosimilar competition in the US market with the launch of Amgen's copycat product Amjevita, several years after it was approved by the FDA.

Any concerns about the loss of U.S. exclusivity for AbbVie's former top-selling drug Humira should be fully alleviated by now. Humira's two successors, Skyrizi and Rinvoq, combined to generate ...

According to Reuters, the grocery retailer notified Express Scripts in September 2022 of its plan to terminate the pharmacy ...

Starting April 1, CVS Health Corp will no longer offer AbbVie Inc’s Humira to most of the millions of patients in its commercial prescription plans. Instead, they’ll be directed to cheaper ...

Learn More » For a while, though, AbbVie might not have been viewed as a fabulous pick by many investors. Humira, the company's top-selling drug for years, lost U.S. patent exclusivity in early 2023.

Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Venclexta sales were $655 million, up 11%. Elahere revenues were $148 million.